Aachen, Germany
PL BioScience GmbH, founded in 2015 and headquartered in Germany, is at the forefront of advancing biotechnology and healthcare. The company specializes in developing Human Platelet Lysate (HPL) through their proprietary ELAREM™ Platform.
With a strong commitment to xeno-free cell culture solutions, PL BioScience aims to replace traditional Fetal Bovine Serum (FBS) with its ethical and sustainable products. Their technology facilitates the transition across all phases of research and therapy from the lab to clinical applications, particularly excelling in regenerative medicine.
Despite being a significant market player, PL BioScience has not disclosed recent funding or investor details. By addressing both academic and clinical needs with its versatile, growth factor-rich HPL, the company sets a high standard in supporting cell expansion innovations.
